BYSUMRI

Allergan Sales, LLC

Application Filed: 2020-06-17
Trademark Application Details
Trademark Logo BYSUMRI
630
Live/Pending
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Research OneLook Acronym Finder
Serial Number90006112
Mark Drawing Code4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form

Timeline

2020-06-17Application Filed
2020-06-20Location: NEW APPLICATION PROCESSING
2020-06-20Status: Live/Pending
2020-06-20Transaction Date

Trademark Applicants & Owners

Owner: Allergan Sales, LLC
Address5 Giralda Farms Madison DE 07940
Legal Entity TypeLimited Liability Company
Legal Entity StateDE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

ALLERGAN SALES, LLC
ALLERGAN SALES, LLC
5 GIRALDA FARMS
MADISON, NJ 07940

Good, Services, and Codes

International Codes:5
U.S. Codes:006,018,044,046,051,052
Type CodeType
GS0051Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Filing History

DescriptionDateEvent Coding
NEW APPLICATION ENTERED IN TRAM2020-06-201 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2020-07-152 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER2020-09-173 DOCK D:Assigned to Examiner
APPROVED FOR PUB - PRINCIPAL REGISTER2020-09-174 CNSA P:
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2020-09-305 NONP E:E-Mail
PUBLISHED FOR OPPOSITION2020-10-206 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2020-10-207 NPUB E:E-Mail
NOA E-MAILED - SOU REQUIRED FROM APPLICANT2020-12-158 NOAM E:E-Mail
TEAS EXTENSION RECEIVED2021-06-089 EEXT I:Incoming Correspondence
EXTENSION 1 FILED2021-06-0810 EXT1 S:
EXTENSION 1 GRANTED2021-06-0811 EX1G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2021-06-1012 EXRA E:E-Mail
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED2021-12-0213 REAP I:Incoming Correspondence
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED2021-12-0214 ARAA I:Incoming Correspondence
TEAS CHANGE OF CORRESPONDENCE RECEIVED2021-12-0215 TCCA I:Incoming Correspondence
TEAS EXTENSION RECEIVED2021-12-0316 EEXT I:Incoming Correspondence
EXTENSION 2 FILED2021-12-0317 EXT2 S:
EXTENSION 2 GRANTED2021-12-0318 EX2G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2021-12-0719 EXRA E:E-Mail
ABANDONMENT - NO USE STATEMENT FILED2022-07-1820 ABN6 S:
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED2022-07-1821 MAB6 E:E-Mail

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed